Three Bridge Wealth Advisors LLC Buys Shares of 27,615 Immunome, Inc. (NASDAQ:IMNM)

Three Bridge Wealth Advisors LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, HoldingsChannel reports. The firm purchased 27,615 shares of the company’s stock, valued at approximately $293,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its holdings in Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after buying an additional 144,557 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after acquiring an additional 85,580 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 252,862 shares of company stock worth $2,140,545 over the last three months. 8.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several analyst reports. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Monday, January 13th. Stephens initiated coverage on shares of Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $28.60.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $10.40 on Thursday. The business has a 50 day moving average price of $11.02 and a 200 day moving average price of $12.51. Immunome, Inc. has a twelve month low of $8.97 and a twelve month high of $30.96.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.